Notably, we found PancVAX2-treated mice had a significant increase in neoantigen-specific CD8+ T cells within the tumor against neoantigens 44, 66, 77, 175, and 219 as measured by IFN-γ secretion (Figure 3F). This evidence concerns the gene CD8A and neoplasm.